Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOURMALINE-AL1: Ixazomib vs Physician's Choice in AL Amyloidosis
NCT01659658Phase 3Terminated
- Sponsor
- Millennium Pharmaceuticals
- Start
- Dec 2012
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 15
01
Overview
A Phase 3 trial of ixazomib in systemic light chain amyloidosis, sponsored by Millennium Pharmaceuticals. Started Dec 2012; status: terminated.
02
Drugs
ixazomib
03
Conditions
systemic light chain amyloidosis
Beyond the preview
Go deeper on NCT01659658.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01659658.